monday class

Downregulation and tachyphylaxis (desensitization)

• Repeated chronic agonist exposure leads to internalization of receptors via endocytosis.
• The cell membrane forms a small vesicle that captures the receptor and pulls it inside the cell.
• Rationale for internalization rather than complete destruction: receptors can be recycled back to the surface when needed, allowing rapid resensitization.
• Destruction via lysosomal degradation would require new transcription, translation, and posttranslational modifications to rebuild receptors, which is slower.
• This process is described clinically as tachyphylaxis or desensitization, a form of tolerance to drug effect.
• If a patient is dosed with an agonist daily, receptor downregulation reduces the response to the same dose over time.
• Consequence: at the same dose, the pharmacodynamic response declines as receptors are internalized.
• Clinically relevant concept: receptor reserve (spare receptors).
• Large receptor reserve means only a small fraction of receptors must be occupied to achieve near-maximal response, so downregulation has a delayed or diminished impact on observed effect.
• If receptor reserve is small, downregulation more quickly depresses maximum effect at a given dose.
• Quantitative intuition: the effect depends on the space between the occupancy curve and the response curve; with a large receptor reserve, occupancy must drop a lot before the effect falls; with little reserve, even small losses in occupancy hit the effect.
• Practical implication for clinicians: drugs acting on receptor systems with large reserve allow more frequent dosing without immediate desensitization; drugs with little reserve show rapid loss of effect and require dose titration.
• The idea of receptor occupancy vs effect can be summarized as: the binding is a prerequisite, but the clinical outcome is governed by the effect curve, influenced by receptor reserve.

Receptor reserve and pharmacodynamics: the occupancy–effect relationship

• Spare receptors enable large changes in occupancy with small changes in effect, up to the ceiling Emax.
• If occupancy falls but effect remains near maximal due to reserve, the observed decline in effect is delayed.
• If receptor reserve is limited, small reductions in receptor occupancy produce noticeable drops in effect.
• The concept is often described as the distance between the binding/occupancy curve and the effect curve; large distance indicates substantial spare capacity before the effect drops markedly.

Binding kinetics: on-rate (kon), off-rate (koff), and affinity (K_D)

• The binding interaction is described by two processes: association (on-rate) and dissociation (off-rate).
• Complex formation is the on reaction; dissociation is the off reaction.
• Affinity is captured by the dissociation constant:
  $K<em>D = \frac{k</em>{\text{off}}}{k_{\text{on}}}$
• kon is diffusion-limited and relatively uniform for small molecules, typically around $k</em>{\text{on}} \approx 10^7\ \text{M}^{-1}\ \text{s}^{-1}$.
• k_off varies widely (milliseconds to hours or longer), generating a wide range of KD values.
• A low KD means high affinity: the drug binds at low concentrations; a high KD means lower affinity.
• The lifespan of the receptor–drug complex is inversely related to koff, often approximated by $\tau \approx \frac{1}{k</em>{\text{off}}}$ for first-order dissociation.
• KD reflects affinity as a product of diffusion/encounter rate and residence time; lower KD corresponds to higher affinity.
• Conceptual takeaway: high affinity (low KD) does not guarantee good drug properties; pharmacokinetics and pharmacodynamics also matter.
• Typical ranges and concepts:
  • k_on varies little across small molecules (roughly a diffusion-limited process).
  • k_off varies widely, driving KD and residence time.
  • Nanomolar KD values are common for many effective drugs; higher KD values (low affinity) require higher concentrations to achieve meaningful binding.
• Practical caveat from cell culture vs in vivo:
  • In cell culture, you can easily apply high molar concentrations to observe binding; in vivo, achieving such concentrations is often impossible due to solubility, distribution, clearance, and safety.
  • An illustrative anecdote: a capstone project noted that in mice, achieving equivalent occupancy observed in cell culture could require injecting a tremendous amount of drug (described as approximately three pounds) to illustrate the scale of dosing challenges.
• Summary relation: $K<em>D = \frac{k</em>{\text{off}}}{k<em>{\text{on}}}$; lower $K</em>D$ = higher binding affinity; fast kon increases encounter rate, slow koff increases residence time.

Dose–response concepts: potency, efficacy, and EC50 vs KD

• Dose–response curves plot percent maximal effect (y-axis) against dose or concentration (x-axis, often on a log scale).
• Potency vs efficacy:
  • Potency reflects the concentration (or dose) required to achieve a given effect; commonly characterized by the half-maximal point: $EC<em>{50}$ (concentration) or $ED</em>{50}$ (dose).
  • Efficacy reflects the maximal effect attainable by the drug (Emax).
• The relationship between occupancy and effect can be described by simple models:
  • Occupancy: $\theta = \frac{[A]}{[A] + K_D}$
  • Observed response: $R = E<em>{\max} \cdot \theta = E</em>{\max} \cdot \frac{[A]}{[A] + K_D}$
  • If using EC50: $R = E<em>{\max} \cdot \frac{[A]}{[A] + EC</em>{50}}$
• Practical interpretation:
  • The EC50 (or ED50) depends on pharmacokinetics and the system studied; it reflects the concentration or dose needed to achieve 50% of the maximal effect in a given setup.
  • KD (affinity) is a property of the ligand–receptor interaction, independent of downstream signaling magnitude; EC50/ED50 reflect both binding and the system's response.
• On a non-log (linear) x-axis, dose–response curves are hyperbolic; on a log x-axis, the curve becomes sigmoidal with a linear middle portion, making it easier to estimate EC50/ED50.
• Partial agonists and antagonists:
  • Partial agonists: bind with affinity but produce a lower maximal effect (lower Emax) than a full agonist; may have different potency (EC50) compared to full agonists depending on the system.
  • Full agonists: achieve near or full Emax.
  • Antagonists: bind with affinity (KD) but have no efficacy (no receptor activation); they block endogenous or exogenous agonists and shift dose–response curves to the right without producing a response alone.
• Interpreting EC50 vs KD:
  • EC50 is not a fixed property of the drug–receptor pair alone; it depends on the system and pharmacokinetics, while KD is a property of the binding interaction itself.
  • In practice, EC50 and KD are related but not identical; EC50 often aligns with the concentration needed to occupy about half the receptors in a simple system, but differences in receptor reserve and signaling can shift this relationship.

Agonists, antagonists, and endogenous ligands

• Agonists: have both affinity (KD) and efficacy (activate receptor) to produce a response.
• Antagonists: have affinity (KD) but no efficacy; they bind to the receptor and block activation, reducing the effect of endogenous agonists.
• Endogenous agonists exist and regulate normal physiology; pharmacology often targets these systems to modulate signaling.
• Example: caffeine is a receptor antagonist for the adenosine receptor. Adenosine is the endogenous agonist that promotes sleepiness via adenosine receptor activation; caffeine blocks this receptor, reducing the sleepy signal.
• Practical implication: many drugs are antagonists, so it's essential to understand both affinity and the ability to block endogenous signaling.

Practical implications, study strategies, and anticipation of next topics

• The next topic will cover what antagonists do in pharmacologic systems and how they differ from agonists in practical terms.
• Real-world considerations include choosing drugs with appropriate affinity, efficacy, and receptor reserve to achieve desired clinical effects with manageable dosing and